A shorter duration of antibiotic treatment versus a longer duration of antibiotic treatment for patients with a flare-up of their chronic lung condition requiring intravenous antibiotics

Phase 4

• Conditions: Bronchiectasis; Respiratory

• Registration Number: ISRCTN14057228
• Lead Sponsor: niversity of Edinburgh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-16
• Last Update Posted: 8 January 2024
• Study Completion: 2025-08-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

1. Adults (age 16 or over)
2. Provision of informed consent (from participant or when lacking capacity due to bronchiectasis severity, by their legal representative)
3. A clinical diagnosis of bronchiectasis made by a respiratory specialist supported by CT scan or equivalent clinical confirmation of bronchiectasis
4. Exacerbation where intravenous antibiotics are deemed clinically appropriate
5. Ability to adhere to the study assessments/protocol in the opinion of the Investigator

Exclusion Criteria

1. Patients who are asymptomatic at start of IV antibiotics
2. Known Homozygous Cystic fibrosis
3. Known active tuberculosis
4. Breast feeding, pregnancy, or plan to become pregnant within study
5. End of life care with anticipated life span less than 6 months
6. Current enrolment in a CTIMP where co-enrolment has not been approved
7. Previous recruitment to the SBIVA trial
8. Allergy to Meropenem and protocol permitted alternatives
9. Where trial enrolment is not in the best interest of the patient in the opinion of the Investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified